Here are five recent GI/endoscopy company news updates.
Actavis will acquire Auden Mckenzie for approximately £306 million, or $460.6 million, in cash as well as a two-year royalty on a percentage of gross profits of one of Auden Mckenzie's products. Auden Mckenzie is a company focused on the development, licensing and marketing of niche generic medicines and proprietary brands in the United Kingdom.
Lawyers from Johnson & Johnson and Boston Scientific presented arguments to a federal judge in a non-jury trial in New York, according to a Reuters report. Johnson & Johnson is seeking $7.2 billion in damages from Boston Scientific, which can be traced back to the bidding contest over Guidant.
Montreal-based biotechnology company enGene closed an $11.5 million Series B investment round that will fund the development of an intestinal gene delivery platform.
Ferring Pharmaceuticals appointed Pascal Danglas, MD, as executive vice president and CMO. The company also appointed Per Falk, MD, PhD, as executive vice president and chief scientific officer.
Prescriptions for Gilead Sciences' hepatitis C drug Harvoni had a 1.8 percent drop in week-over-week prescriptions for the week ending Jan. 16, but AbbVie's HCV treatment Viekira Pak had an increase of 55 percent, according to a Bidness ETC report.
If you have a question, issue or note to suggest on a GI/endoscopy company please contact Carrie Pallardy at cpallardy@beckershealthcare.com.